Manon C Spaander

List of Publications by Year
in descending order

190 papers	6,678 citations	66343 42 h-index	82547 72 g-index
193 all docs	193 docs citations	193 times ranked	7266 citing authors

#	Article	IF	Citations
1	Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. Gut, 2023, 72, 101-108.	12.1	8
2	Population-Based Prevalence of Gastrointestinal Abnormalities at Colon Capsule Endoscopy. Clinical Gastroenterology and Hepatology, 2022, 20, 692-700.e7.	4.4	8
3	Favorable effect of endoscopic reassessment of clinically staged T2 esophageal adenocarcinoma: a multicenter prospective cohort study. Endoscopy, 2022, 54, 163-169.	1.8	3
4	Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas. Clinical Gastroenterology and Hepatology, 2022, 20, e496-e507.	4.4	14
5	Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkinâ€™s lymphoma survivors. Digestive Endoscopy, 2022, 34, 163-170.	2.3	1
6	Continuous monitoring of colonoscopy performance in the Netherlands: first results of a nationwide registry. Endoscopy, 2022, 54, 488-495.	1.8	9
7	Artificial Intelligence in Upper Gastrointestinal Endoscopy. Digestive Diseases, 2022, 40, 395-408.	1.9	10
8	Gastric cancer incidence and mortality trends 2007â€“2016 in three European countries. Endoscopy, 2022, 54, 644-652.	1.8	10
9	Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. The Lancet Gastroenterology and Hepatology, 2022, 7, 60-68.	8.1	42
10	Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands. European Journal of Cancer, 2022, 161, 38-43.	2.8	28
11	Accuracy of H. pylori fecal antigen test using fecal immunochemical test (FIT). Gastric Cancer, 2022, 25, 375-381.	5.3	7
12	First genome-wide association study of esophageal atresia identifies three genetic risk loci at CTNNA3, FOXF1/FOXC2/FOXL1, and HNF1B. Human Genetics and Genomics Advances, 2022, 3, 100093.	1.7	4
13	Impact of expert center endoscopic assessment of confirmed low grade dysplasia in Barrettâ€™s esophagus diagnosed in community hospitals. Endoscopy, 2022, 54, 936-944.	1.8	10
14	Intrinsic Cellular Susceptibility to Barrettâ€™s Esophagus in Adults Born with Esophageal Atresia. Cancers, 2022, 14, 513.	3.7	3
15	Recommendations for endoscopic surveillance after esophageal atresia repair in adults. Ecological Management and Restoration, 2022, 35, .	0.4	5
16	Impact of surgical versus endoscopic management of complex nonmalignant polyps in a colorectal cancer screening program. Endoscopy, 2022, 54, 871-880.	1.8	4
17	Autophagy mediates ER stress and inflammation in Helicobacter pylori -related gastric cancer. Gut Microbes, 2022, 14, 2015238.	9.8	22
18	A personalized and dynamic risk estimation model: The new paradigm in Barrettâ€™s esophagus surveillance. PLoS ONE, 2022, 17, e0267503.	2.5	0

#	Article	IF	Citations
19	Self-expandable duodenal metal stent placement for the palliation of gastric outlet obstruction over the past 20 years. Endoscopy, 2022, 54, 1139-1146.	1.8	4
20	Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study. The Lancet Gastroenterology and Hepatology, 2022, 7, 747-754.	8.1	40
21	Predictors of Gastrointestinal Transit Times in Colon Capsule Endoscopy. Clinical and Translational Gastroenterology, 2022, 13, e00498.	2.5	2
22	Effect of the COVID-19 pandemic on procedure volumes in gastroenterology in the Netherlands. The Lancet Gastroenterology and Hepatology, 2022, 7, 595-598.	8.1	4
23	Bite-on-bite biopsies for the detection of residual esophageal cancer after neoadjuvant chemoradiotherapy. Endoscopy, 2022, 54, 1131-1138.	1.8	1
24	Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic. PLoS ONE, 2022, 17, e0270223.	2.5	0
25	Sex Differences in Neoplastic Progression in Barrettâ€™s Esophagus: A Multicenter Prospective Cohort Study. Cancers, 2022, 14, 3240.	3.7	2
26	Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Annals of Surgery, 2021, 274, 1009-1016.	4.2	38
27	Colonoscopy-Related Mortality in a Fecal Immunochemical Testâ€“Based Colorectal Cancer Screening Program. Clinical Gastroenterology and Hepatology, 2021, 19, 1418-1425.	4.4	12
28	An international survey on anastomotic stricture management after esophageal atresia repair: considerations and advisory statements. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 3653-3661.	2.4	8
29	Early diagnosis is associated with improved clinical outcomes in benign esophageal perforation: an individual patient data meta-analysis. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 3492-3505.	2.4	20
30	Increased risk of second primary tumours in patients with oesophageal squamous cell carcinoma: a nationwide study in a Western population. United European Gastroenterology Journal, 2021, 9, 497-506.	3.8	13
31	Recent advances in the detection and management of early gastric cancer and its precursors. Frontline Gastroenterology, 2021, 12, 322-331.	1.8	34
32	Surveillance of Clinically Complete Responders Using Serial ¹⁸F-FDG PET/CT Scans in Patients with Esophageal Cancer After Neoadjuvant Chemoradiotherapy. Journal of Nuclear Medicine, 2021, 62, 486-492.	5.0	11
33	Accuracy of upper endoscopies with random biopsies to identify patients with gastric premalignant lesions who can safely be exempt from surveillance. Gastric Cancer, 2021, 24, 680-690.	5.3	7
34	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. BMC Gastroenterology, 2021, 21, 67.	2.0	2
35	Impact of the Implementation of the Dutch National fit-based CRC Screening Program on Incidence and Characteristics of Screen-Detected CRCS. Endoscopy, 2021, 53, .	1.8	0
36	Predictors Of Gastrointestinal Transit Times In Colon Capsule Endoscopy. Endoscopy, 2021, 53, .	1.8	0

#	Article	IF	Citations
37	Predictive value of endoscopic esophageal findings for residual esophageal cancer after neoadjuvant chemoradiotherapy. Endoscopy, 2021, 53, 1098-1104.	1.8	6
38	Screening for Synchronous Esophageal Second Primary Tumors in Patients With Head and Neck Cancer. , 2021, 53, .		0
39	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline â€“ Update 2021. Endoscopy, 2021, 53, 751-762.	1.8	63
40	HOXA13 in etiology and oncogenic potential of Barrettâ€™s esophagus. Nature Communications, 2021, 12, 3354.	12.8	5
41	Screening for synchronous esophageal second primary tumors in patients with head and neck cancer. Ecological Management and Restoration, 2021, 34, .	0.4	6
42	Clinical Validation of a Multitarget Fecal Immunochemical Test for Colorectal Cancer Screening. Annals of Internal Medicine, 2021, 174, 1224-1231.	3.9	16
43	Endoscopic tissue sampling â€“ Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2021, 53, 1174-1188.	1.8	71
44	The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic. Preventive Medicine, 2021, 151, 106643.	3.4	32
45	Patient-driven healthcare recommendations for adults with esophageal atresia and their families. Journal of Pediatric Surgery, 2021, 56, 1932-1939.	1.6	11
46	Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers. Cancers, 2021, 13, 459.	3.7	2
47	Low Risk of Progression of Barrettâ€™s Esophagus to Neoplasia in Women. Journal of Clinical Gastroenterology, 2021, 55, 321-326.	2.2	11
48	Clinicopathological characteristics of early onset colorectal cancer. Alimentary Pharmacology and Therapeutics, 2021, 54, 1463-1471.	3.7	10
49	Endoscopic tissue sampling â€“ Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2021, 53, 1261-1273.	1.8	30
50	Applicability of colon capsule endoscopy as pan-endoscopy: From bowel preparation, transit, and rating times to completion rate and patient acceptance. Endoscopy International Open, 2021, 09, E1852-E1859.	1.8	11
51	Editorial: machine learning models for gastric cancer risk prediction. Alimentary Pharmacology and Therapeutics, 2021, 53, 943-944.	3.7	1
52	Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study. Gut, 2020, 69, 112-121.	12.1	43
53	Adherence to recommendations of Barrettâ€™s esophagus surveillance guidelines: a systematic review and meta-analysis. Endoscopy, 2020, 52, 17-28.	1.8	39
54	Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. Clinical Gastroenterology and Hepatology, 2020, 18, 1493-1500.	4.4	29

#	Article	IF	Citations
55	Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2020, 18, 667-675.e1.	4.4	38
56	Yield of Lynch Syndrome Surveillance for Patients With Pathogenic Variants in DNA Mismatch Repair Genes. Clinical Gastroenterology and Hepatology, 2020, 18, 1112-1120.e1.	4.4	14
57	A Quarter of Participants With Advanced Neoplasia Have Discordant Results From 2-Sample Fecal Immunochemical Tests for Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2020, 18, 1805-1811.e1.	4.4	6
58	Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. Clinical Gastroenterology and Hepatology, 2020, 18, 2760-2767.e12.	4.4	8
59	Endoscopic ultrasound and fine-needle aspiration for the detection of residual nodal disease after neoadjuvant chemoradiotherapy for esophageal cancer. Endoscopy, 2020, 52, 186-192.	1.8	6
60	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cutâ€•off level on yield of screening. International Journal of Cancer, 2020, 147, 1098-1106.	5.1	29
61	Stents for benign esophageal strictures. Techniques and Innovations in Gastrointestinal Endoscopy, 2020, 22, 200-204.	0.9	2
62	Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial. British Journal of Surgery, 2020, 107, 1791-1800.	0.3	11
63	Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study. BMC Cancer, 2020, 20, 194.	2.6	22
64	A European, multicentre, observational, post-authorisation safety study of oral sulphate solution: compliance and safety. Endoscopy International Open, 2020, 08, E247-E256.	1.8	3
65	The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management. American Journal of Gastroenterology, 2020, 115, 1026-1035.	0.4	1
66	Dutch Gastrointestinal Endoscopy Audit: automated extraction of colonoscopy data for quality assessment and improvement. Gastrointestinal Endoscopy, 2020, 92, 154-162.e1.	1.0	16
67	Diagnostic Accuracy of Stool Tests for Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors. Journal of Clinical Medicine, 2020, 9, 190.	2.4	5
68	Substantial and sustained improvement of serrated polyp detection after a simple educational intervention: results from a prospective controlled trial. Gut, 2020, 69, 2150-2158.	12.1	19
69	Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut, 2019, 68, 585-593.	12.1	94
70	Effect of anticoagulants and NSAIDs on accuracy of faecal immunochemical tests (FITs) in colorectal cancer screening: a systematic review and meta-analysis. Gut, 2019, 68, 866-872.	12.1	26
71	Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. Gut, 2019, 68, 873-881.	12.1	48
72	Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrettâ€™s Esophagus to Esophageal Adenocarcinoma. Clinical Gastroenterology and Hepatology, 2019, 17, 864-868.	4.4	51

#	Article	IF	Citations
73	Self-expandable metal stent placement for malignant esophageal strictures â€“ changes in clinical outcomes over time. Endoscopy, 2019, 51, 18-29.	1.8	51
74	A novel device for intracolonoscopy cleansing of inadequately prepared colonoscopy patients: a feasibility study. Endoscopy, 2019, 51, 85-92.	1.8	19
75	Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma. PLoS ONE, 2019, 14, e0219494.	2.5	7
76	Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study. The Lancet Gastroenterology and Hepatology, 2019, 4, 622-631.	8.1	27
77	Targeting Tyrosine Phosphatases by 3-Bromopyruvate Overcomes Hyperactivation of Platelets from Gastrointestinal Cancer Patients. Journal of Clinical Medicine, 2019, 8, 936.	2.4	10
78	Through-the-scope placement of a fully covered metal stent for palliation of malignant dysphagia: a prospective cohort study (with video). Gastrointestinal Endoscopy, 2019, 90, 972-979.	1.0	8
79	Endoscopic grading of gastric intestinal metaplasia: can we do it without pathologists?. Endoscopy, 2019, 51, 509-510.	1.8	0
80	Achalasia and associated esophageal cancer risk: What lessons can we learn from the molecular analysis of Barrett'sâ€“associated adenocarcinoma?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1872, 188291.	7.4	12
81	Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut, 2019, 68, 1820-1826.	12.1	463
82	Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy. Gastroenterology, 2019, 156, 2198-2207.e1.	1.3	64
83	Accuracy of ¹⁸F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. Journal of Nuclear Medicine, 2019, 60, 1553-1559.	5.0	25
84	Effects of Oral Anticoagulant and Aspirin Use on Ability of Fecal Immunochemical Tests to Detect Advanced Neoplasia. Gastroenterology, 2019, 156, 1553-1555.	1.3	2
85	Treatment of refractory post-esophagectomy anastomotic esophageal strictures using temporary fully covered esophageal metal stenting compared to repeated bougie dilation: results of a randomized controlled trial. Endoscopy International Open, 2019, 07, E178-E185.	1.8	9
86	Intralesional steroid injections to prevent refractory strictures in patients with oesophageal atresia: study protocol for an international, multicentre randomised controlled trial (STEPS-EA trial). BMJ Open, 2019, 9, e033030.	1.9	2
87	Accuracy of endoscopic staging and targeted biopsies for routine gastric intestinal metaplasia and gastric atrophy evaluation study protocol of a prospective, cohort study: the estimate study. BMJ Open, 2019, 9, e032013.	1.9	3
88	Evaluation of Gastroesophageal Reflux in Children Born With Esophageal Atresia Using pH and Impedance Monitoring. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 515-522.	1.8	19
89	Participation and Ease of Use in Colorectal Cancer Screening: A Comparison of 2 Fecal Immunochemical Tests. American Journal of Gastroenterology, 2019, 114, 511-518.	0.4	12
90	Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Digestive Surgery, 2019, 36, 462-469.	1.2	23

#	Article	IF	Citations
91	High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors. Cancer, 2019, 125, 990-999.	4.1	23
92	Quality assurance of colonoscopy within the Dutch national colorectal cancer screening program. Gastrointestinal Endoscopy, 2019, 89, 1-13.	1.0	48
93	FACTORS ASSOCIATED WITH THE PROGRESSION OF GASTRIC INTESTINAL METAPLASIA IN A LOW RISK POPULATION â€“ A MULTICENTER, PROSPECTIVE COHORT STUDY. , 2019, 51, .		0
94	Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program. Clinical Gastroenterology and Hepatology, 2018, 16, 1237-1243.e2.	4.4	21
95	High Prevalence of Barrettâ€™s Esophagus and Esophageal Squamous Cell Carcinoma After Repair of Esophageal Atresia. Clinical Gastroenterology and Hepatology, 2018, 16, 513-521.e6.	4.4	40
96	Development and Validation of a Model to Determine Risk of Progression of Barrettâ€™s Esophagus to Neoplasia. Gastroenterology, 2018, 154, 1282-1289.e2.	1.3	107
97	Personalized screening for colorectal cancer. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 391-392.	17.8	15
98	Stage distribution of screen-detected colorectal cancers in the Netherlands. Gut, 2018, 67, 1745-1746.	12.1	37
99	Stent placement for benign esophageal leaks, perforations, and fistulae: a clinical prediction rule for successful leakage control. Endoscopy, 2018, 50, 98-108.	1.8	28
100	Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers. Familial Cancer, 2018, 17, 361-370.	1.9	8
101	Germline variant in MSX1 identified in a Dutch family with clustering of Barrettâ€™s esophagus and esophageal adenocarcinoma. Familial Cancer, 2018, 17, 435-440.	1.9	5
102	Palliation of dysphagia. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 97-103.	2.4	21
103	Neoadjuvant chemoradiotherapy for resectable oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 37-44.	2.4	15
104	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. Gastroenterology, 2018, 155, 1392-1399.e5.	1.3	16
105	Routine Molecular Analysis for Lynch Syndrome Among Adenomas or Colorectal Cancer Within a National Screening Program. Gastroenterology, 2018, 155, 1410-1415.	1.3	9
106	Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncology, The, 2018, 19, 965-974.	10.7	211
107	Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial. BMC Cancer, 2018, 18, 142.	2.6	166
108	Improved Progression Prediction in Barrettâ€™s Esophagus With Low-grade Dysplasia Using Specific Histologic Criteria. American Journal of Surgical Pathology, 2018, 42, 918-926.	3.7	14

#	Article	IF	Citations
109	Fully vs. partially covered selfexpandable metal stent for palliation of malignant esophageal strictures: a randomized trial (the COPAC study). Endoscopy, 2018, 50, 961-971.	1.8	50
110	Natural History of Barrettâ€™s Esophagus. Digestive Diseases and Sciences, 2018, 63, 1997-2004.	2.3	30
111	P53 and SOX2 Protein Expression Predicts Esophageal Adenocarcinoma in Response to Neoadjuvant Chemoradiotherapy. Annals of Surgery, 2017, 265, 347-355.	4.2	9
112	Prevalence of Barrett Esophagus in Adolescents and Young Adults With Esophageal Atresia. Annals of Surgery, 2017, 266, e95-e96.	4.2	2
113	A randomised comparison of two faecal immunochemical tests in population-based colorectal cancer screening. Gut, 2017, 66, 1975-1982.	12.1	43
114	Paediatric Gastrointestinal Endoscopy. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 133-153.	1.8	186
115	Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing. Gastroenterology, 2017, 153, 439-447.e2.	1.3	56
116	Optimizing Fecal Immunochemical Testing For Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2017, 15, 1498-1499.	4.4	0
117	Exploring diagnostic and therapeutic implications of endoscopic mucosal resection in EUS-staged T2 esophageal adenocarcinoma. Endoscopy, 2017, 49, 941-948.	1.8	13
118	Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1328-1336.	2.5	14
119	Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples. BMC Research Notes, 2017, 10, 144.	1.4	10
120	Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?. Gut, 2017, 66, 1262-1267.	12.1	18
121	Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. British Journal of Cancer, 2017, 116, 44-49.	6.4	65
122	Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy. Gastroenterology, 2017, 152, 987-992.	1.3	54
123	Surveillance after curative treatment for colorectal cancer. Nature Reviews Clinical Oncology, 2017, 14, 297-315.	27.6	177
124	Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. Gastroenterology, 2017, 153, 1251-1259.e2.	1.3	45
125	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. BMC Cancer, 2017, 17, 112.	2.6	8
126	Does Routine Endoscopy or Contrast Swallow Study After Esophagectomy and Gastric Tube Reconstruction Change Patient Management?. Journal of Gastrointestinal Surgery, 2017, 21, 251-258.	1.7	17

#	Article	IF	Citations
127	Real-Time Monitoring of Results During First Year ofÂDutchÂColorectal Cancer Screening Program andÂOptimizationÂbyÂAltering Fecal Immunochemical TestÂCut-OffÂLevels. Gastroenterology, 2017, 152, 767-775.e2.	1.3	179
128	Variable Quality and Readability of Patient-oriented Websites on Colorectal Cancer Screening. Clinical Gastroenterology and Hepatology, 2017, 15, 79-85.e3.	4.4	25
129	Pediatric gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) Guideline Executive summary. Endoscopy, 2017, 49, 83-91.	1.8	136
130	Surgery for a large tracheoesophageal fistula using extracorporeal membrane oxygenation. Journal of Thoracic Disease, 2017, 9, E735-E738.	1.4	4
131	Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity. PLoS Genetics, 2017, 13, e1006765.	3.5	18
132	Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0186305.	2.5	27
133	Population-Based Colonoscopy Screening for Colorectal Cancer. JAMA Internal Medicine, 2016, 176, 894.	5.1	258
134	Do we need to fixate a fully covered esophageal metal stent?. Endoscopy, 2016, 48, 787-788.	1.8	3
135	Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program. Clinical Gastroenterology and Hepatology, 2016, 14, 1771-1777.	4.4	20
136	Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy, 2016, 48, 939-948.	1.8	257
137	Early pain detection and management after esophageal metal stent placement in incurable cancer patients: A prospective observational cohort study. Endoscopy International Open, 2016, 04, E890-E894.	1.8	13
138	Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance. Medicine (United States), 2016, 95, e5402.	1.0	8
139	Accrediting for screening-related colonoscopy services: What is required of the endoscopist and of the endoscopy service?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 487-495.	2.4	9
140	Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genetics in Medicine, 2016, 18, 966-973.	2.4	42
141	Advances in Fecal Tests for Colorectal Cancer Screening. Current Treatment Options in Gastroenterology, 2016, 14, 152-162.	0.8	37
142	Colorectal Cancer Screening by Colonoscopy, CT-Colonography, or Fecal Immunochemical Test. Journal of the National Cancer Institute, 2016, 108, djv383.	6.3	8
143	Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression. Gut, 2016, 65, 548-554.	12.1	59
144	Cost-Effectiveness of Cetuximab for Advanced Esophageal Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0153943.	2.5	8

#	Article	IF	Citations
145	Early onset esophageal adenocarcinoma: a distinct molecular entity?. Oncoscience, 2016, 3, 42-48.	2.2	9
146	Improved body weight and performance status and reduced serum PGE₂ levels after nutritional intervention with a specific medical food in newly diagnosed patients with esophageal cancer or adenocarcinoma of the gastroâ€esophageal junction. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 32-44.	7.3	35
147	Absence or low IGFâ€1Râ€expression in esophageal adenocarcinoma is associated with tumor invasiveness and radicality of surgical resection. Journal of Surgical Oncology, 2015, 111, 1047-1053.	1.7	5
148	Vitamin D Receptor Polymorphisms Are Associated with Reduced Esophageal Vitamin D Receptor Expression and Reduced Esophageal Adenocarcinoma Risk. Molecular Medicine, 2015, 21, 346-354.	4.4	12
149	Second-Look Colonoscopies and the Impact on Capacity in FIT-Based Colorectal Cancer Screening. American Journal of Gastroenterology, 2015, 110, 1072-1077.	0.4	7
150	NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open, 2015, 5, e006640-e006640.	1.9	43
151	Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrettâ€™s Esophagus. Gastroenterology, 2015, 148, 367-378.	1.3	93
152	Acid suppression and surgical therapy for Barrett's oesophagus. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 139-150.	2.4	4
153	Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis. Gut, 2015, 64, 864-871.	12.1	63
154	Comparison of cecal intubation and adenoma detection between hospitals can provide incentives to improve quality of colonoscopy. Endoscopy, 2015, 47, 703-709.	1.8	16
155	Screening and Surveillance in Esophageal Atresia Patients: Current Knowledge and Future Perspectives. European Journal of Pediatric Surgery, 2015, 25, 345-352.	1.3	27
156	SOX2 as a Novel Marker to Predict Neoplastic Progression in Barrettâ€™s Esophagus. American Journal of Gastroenterology, 2015, 110, 1420-1428.	0.4	24
157	Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Research Protocols, 2015, 4, e79.	1.0	69
158	Single nucleotide polymorphisms in CRTC1 and BARX1 are associated with esophageal adenocarcinoma. Journal of Carcinogenesis, 2015, 14, 5.	2.5	14
159	Hereditary Factors in Esophageal Adenocarcinoma. Gastrointestinal Tumors, 2014, 1, 93-98.	0.7	17
160	Endoscopic treatment of malignant gastric and duodenal strictures: a prospective, multicenter study. Gastrointestinal Endoscopy, 2014, 79, 66-75.	1.0	108
161	Location of Lymph Node Involvement in Patients with Esophageal Adenocarcinoma Predicts Survival. World Journal of Surgery, 2014, 38, 106-113.	1.6	22
162	Treatment and outcome of young patients with esophageal cancer in the Netherlands. Journal of Surgical Oncology, 2014, 109, 561-566.	1.7	15

#	Article	IF	Citations
163	Glutathione peroxidase 7 prevents cancer in the oesophagus. Gut, 2014, 63, 537-538.	12.1	9
164	Nurse-Led Follow-Up at Home vs. Conventional Medical Outpatient Clinic Follow-Up in Patients With Incurable Upper Gastrointestinal Cancer: A Randomized Study. Journal of Pain and Symptom Management, 2014, 47, 518-530.	1.2	27
165	Esophageal Stents in Malignant and Benign Disorders. Current Gastroenterology Reports, 2013, 15, 319.	2.5	41
166	Anticoagulant therapy in patients with non-cirrhotic portal vein thrombosis: effect on new thrombotic events and gastrointestinal bleeding. Journal of Thrombosis and Haemostasis, 2013, 11, 452-459.	3.8	89
167	Efficacy and safety of a partially covered stent in malignant gastric outlet obstruction: a prospective Western series. Gastrointestinal Endoscopy, 2013, 77, 664-668.	1.0	14
168	624 SELF-EXPANDABLE METAL STENTS AS DEFINITE TREATMENT FOR ESOPHAGEAL VARICEAL BLEEDING. Journal of Hepatology, 2013, 58, S255.	3.7	1
169	Preoperative Assessment of Tumor Location and Stationâ€Specific Lymph Node Status in Patients with Adenocarcinoma of the Gastroesophageal Junction. World Journal of Surgery, 2013, 37, 147-155.	1.6	62
170	Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2013, 11, 382-388.	4.4	182
171	Accuracy of narrow-band imaging in predicting colonoscopy surveillance intervals and histology of distal diminutive polyps: results from a multicenter, prospective trial. Gastrointestinal Endoscopy, 2013, 78, 106-114.	1.0	54
172	Impact of a multidisciplinary tumour board meeting for upper-GI malignancies on clinical decision making: a prospective cohort study. International Journal of Clinical Oncology, 2013, 18, 214-219.	2.2	79
173	Self-expandable metal stents as definitive treatment for esophageal variceal bleeding. Endoscopy, 2013, 45, 485-488.	1.8	38
174	Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut, 2013, 62, 1676-1683.	12.1	214
175	Value of Î±â€methylacylâ€CoA racemase immunochemistry for predicting neoplastic progression in Barrett's oesophagus. Histopathology, 2013, 63, 630-639.	2.9	28
176	Improving the quality of pretreatment staging in patients with esophageal carcinoma â€“ a fast track study. Acta OncolÃ³gica, 2012, 51, 362-367.	1.8	3
177	Endoscopic removal of a broken self-expandable metal stent using the stent-in-stent technique. Endoscopy, 2012, 44, E232-E232.	1.8	7
178	Recordings of consultations are beneficial in the transition from curative to palliative cancer care: A pilot-study in patients with oesophageal or head and neck cancer. European Journal of Oncology Nursing, 2012, 16, 109-114.	2.1	14
179	Safety of stent placement in recurrent or persistent esophageal cancer after definitive chemoradiotherapy: a case series. Gastrointestinal Endoscopy, 2012, 76, 426-430.	1.0	15
180	Nonsteroidal Anti-Inflammatory Drugs and Statins Have Chemopreventative Effects in Patients With Barrett's Esophagus. Gastroenterology, 2011, 141, 2000-2008.	1.3	119

#	Article	IF	Citations
181	Longâ€term followâ€up of patients with portal vein thrombosis and myeloproliferative neoplasms. Journal of Thrombosis and Haemostasis, 2011, 9, 2208-2214.	3.8	68
182	Role of Acid Suppression in the Development and Progression of Dysplasia in Patients with Barrettâ€™s Esophagus. Digestive Diseases, 2011, 29, 499-506.	1.9	18
183	Delay in Diagnostic Workup and Treatment of Esophageal Cancer. Journal of Gastrointestinal Surgery, 2010, 14, 476-483.	1.7	57
184	Ascites in patients with noncirrhotic nonmalignant extrahepatic portal vein thrombosis. Alimentary Pharmacology and Therapeutics, 2010, 32, 529-534.	3.7	25
185	Esophageal stents for the relief of malignant dysphagia due to extrinsic compression. Endoscopy, 2010, 42, 536-540.	1.8	29
186	A new fully covered stent with antimigration properties for the palliation of malignant dysphagia: a prospective cohort study. Gastrointestinal Endoscopy, 2010, 71, 600-605.	1.0	75
187	Esophageal stents for the palliation of malignant dysphagia and fistula recurrence after esophagectomy. Gastrointestinal Endoscopy, 2010, 72, 249-254.	1.0	38
188	Short-Term Esophageal Stenting in the Management of Benign Perforations. American Journal of Gastroenterology, 2010, 105, 1515-1520.	0.4	122
189	M1958 Twelve Years Experience with Self Expandable Stents for Malignant Esophageal Strictures in 592 Patients; Has the Outcome Improved Over the Years?. Gastroenterology, 2009, 136, A-455.	1.3	1
190	Endoscopic treatment of esophagogastric variceal bleeding in patients with noncirrhotic extrahepatic portal vein thrombosis: a long-term follow-up study. Gastrointestinal Endoscopy, 2008, 67, 821-827.	1.0	46